DailyMarkets.com
GlaxoSmithKline's (NYSE:GSK) efforts to get its prostate cancer drug, Avodart, approved for an additional indication faced a stumbling block recently with an advisory panel of the US Food and Drug Administration (FDA) voting against the label expansion.
- FDA Wants More Data on Valeant-Glaxo Epilepsy Drug - Drugs.com - Pharma News
- Do Food Dyes Harm Kids? The FDA Finally Wants to Know - Change.org's Sustainable Food Blog
- FDA Clears GeNO LLC's Investigational New Drug Application for Clinical Trials With Its NITROSYLâ„¢ Inhaled Nitric Oxide System - Pharmainfo.net
Posts
0 comments:
Post a Comment